4.16
1.19%
-0.05
Schlusskurs vom Vortag:
$4.21
Offen:
$4.23
24-Stunden-Volumen:
317.80K
Marktkapitalisierung:
$247.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.54M
KGV:
-4.6742
EPS:
-0.89
Netto-Cashflow:
$-30.33M
1W Leistung:
+5.85%
1M Leistung:
+0.24%
6M Leistung:
+88.24%
1J Leistung:
-59.14%
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Firmenname
Aldeyra Therapeutics Inc
Sektor
Branche
Telefon
781-761-4904
Adresse
131 Hartwell Avenue, Suite 320, Lexington, MA
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2022-04-27 | Fortgesetzt | H.C. Wainwright | Buy |
2021-02-08 | Eingeleitet | H.C. Wainwright | Buy |
2020-12-16 | Eingeleitet | Berenberg | Buy |
2020-10-30 | Eingeleitet | Jefferies | Buy |
2020-10-16 | Eingeleitet | BTIG Research | Buy |
2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
2020-05-12 | Eingeleitet | Oppenheimer | Outperform |
2018-12-04 | Eingeleitet | Citigroup | Buy |
2018-09-26 | Bestätigt | Cantor Fitzgerald | Overweight |
2018-09-13 | Eingeleitet | Janney | Buy |
2018-01-26 | Eingeleitet | Seaport Global Securities | Buy |
2016-09-26 | Eingeleitet | H.C. Wainwright | Buy |
2016-07-01 | Eingeleitet | Stifel | Buy |
2015-07-01 | Eingeleitet | Canaccord Genuity | Buy |
2015-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
2015-03-20 | Bestätigt | H.C. Wainwright | Buy |
2014-11-18 | Eingeleitet | H.C. Wainwright | Buy |
2014-06-19 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Zacks Investment Research
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Zacks Investment Research
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Benzinga
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Zacks Investment Research
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
Finanzdaten der Aldeyra Therapeutics Inc-Aktie (ALDX)
Aldeyra Therapeutics Inc (ALDX) Nettogewinn 2024
ALDX betrug am 2023-12-31 der Nettogewinn der letzten 12 Monate -37.54 Millionen US-Dollar, was einem Anstieg von +39.47% im Vergleich zum Vorjahr entspricht.
Aldeyra Therapeutics Inc (ALDX) Free Cashflow 2024
ALDX verzeichnete einen Free Cashflow der letzten 12 Monate von -30.33 Millionen US-Dollar für das Quartal bis zum 2023-12-31, was einem Anstieg von +46.47% im Vergleich zum Vorjahr entspricht.
Aldeyra Therapeutics Inc (ALDX) Gewinn je Aktie 2024
Der Gewinn je Aktie (EPS) von ALDX für die letzten 12 Monate betrug -0.64 US-Dollar für das Quartal, das am 2023-12-31 endete, was einem Wachstum von +39.62% im Vergleich zum Vorjahr entspricht.
Aldeyra Therapeutics Inc-Aktie (ALDX) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 04 '24 |
Buy |
4.67 |
140,281 |
655,112 |
9,238,139 |
PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 03 '24 |
Buy |
4.09 |
309,847 |
1,267,274 |
9,097,858 |
PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 02 '24 |
Buy |
3.44 |
186,051 |
640,015 |
8,788,011 |
PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 01 '24 |
Buy |
3.25 |
8,374 |
27,216 |
8,601,960 |
Brady Todd C | President and CEO |
Mar 12 '24 |
Sale |
3.05 |
85,324 |
260,238 |
1,471,298 |
Machatha Stephen | Chief Development Officer |
Mar 12 '24 |
Sale |
3.16 |
11,537 |
36,503 |
243,495 |
Brady Todd C | President and CEO |
Mar 11 '24 |
Sale |
3.27 |
97,914 |
320,521 |
1,556,622 |
Machatha Stephen | Chief Development Officer |
Mar 11 '24 |
Sale |
3.41 |
18,231 |
62,102 |
255,032 |
Greenberg Bruce | See Remarks |
Mar 11 '24 |
Sale |
3.41 |
13,201 |
44,968 |
120,699 |
PERCEPTIVE ADVISORS LLC | 10% Owner |
Oct 18 '23 |
Sale |
1.74 |
306,499 |
533,308 |
8,593,586 |
Kapitalisierung:
|
Volumen (24h):